SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quants sharp rally is being linked to community attention around reported Oracle and Clearing House work on bank and tokenized-asset infrastructure, alongside expectations of institutional adoption and a limited token supply. Traders are split between seeing the partnerships as a long-term demand catalyst and questioning whether they will translate into meaningful QNT token use, with volatile pullbacks prompting profit-taking and dip-buying.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors 24-month HOPE-3 extension data presented at the World Muscle Society, including a reported slowing of upper-limb decline after patients switched to deramiocel, is driving attention ahead of the FDAs November decision. Traders largely view the results as supportive of approval, while others question whether the data resolve the FDAs concerns about the trials statistical analysis and efficacy claims.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised 2026 revenue outlook, reflecting stronger demand for Amtagvi and Proleukin, is driving the sharp rally and bullish discussion, with traders also pointing to analyst upgrades. Many expect upcoming lung-cancer data to add momentum, while others warn the stock may be overextended and debate whether short covering is amplifying the move.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A steep selloff to multi-year lows is being blamed on slowing ad growth, weak advertising-spend expectations, and competition from Amazon and other large platforms; traders also debate whether an Apple Safari ad-serving issue adds a meaningful risk or was an unintended bug. Bearish frustration over management and the business outlook dominates, while some investors point to the companys cash generation and view the stock as oversold.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

A federal judges pause in the broader cannabis rescheduling proceeding, while considering whether to add a GAO report on agency procedures to the record, has delayed the anticipated Schedule III recommendation. Traders are divided between viewing the pause as a damaging setback that could prolong uncertainty and treating it as a procedural delay or overreaction, with some buying the selloff.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings sharp decline is being tied to concerns that Kalshi and Polymarket are taking wagering share, while heavier spending to build DraftKings own prediction-market business could pressure margins; traders also point to regulatory uncertainty and scrutiny of its promotional practices. Bulls counter that DKeX volumes and sportsbook activity are growing, arguing the investment could pay off, while bears question whether that growth can be monetized profitably.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FICO is under pressure after the FHFA put VantageScore alongside FICO on the mortgage pricing grid, raising the prospect that lenders could use the cheaper alternative and weakening FICOs mortgage-scoring pricing power. Bears see a threat to its moat and future revenue, while bulls argue adoption is not guaranteed and the selloff overstates the impact on an established business.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Positive Phase III results for Vandas HETLIOZ in delayed sleep-wake phase disorder are the main catalyst; the study met its primary endpoint, and the company plans to discuss the data with the FDA before pursuing a label expansion. Traders see a potential new commercial opportunity and speculate about buyout interest, while some question the small trial size and the opportunity given generic competition.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

A sharp COMP rebound has traders calling a technical breakout, with bullish posts citing its capped supply and betting on a broader DeFi and altcoin recovery; others remain skeptical about its relative performance and fundamentals. Speculation around upcoming crypto market-structure legislation also appears in the discussion, but is not established as the immediate catalyst.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A new indirect comparison suggesting Lillys Foundayo outperformed Novos oral semaglutide on weight loss and blood sugar has renewed discussion of the companies competition in oral GLP-1s. Traders debate how meaningful the comparison is because it draws on separate trials, while some point to Foundayos prescription growth as a sign it is gaining traction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
